Why the study?
Anticoagulation treatment patterns, health care resource use, and clinical characteristics in adult patients with non-valvular atrial fibrillation (NVAF) needed evaluation in an Italian real-world setting.
Do NOACs compared to VKAs reduce bleeding events and healthcare resource use in adult patients with non-valvular atrial fibrillation?
Do NOACs compared to VKAs reduce bleeding events and healthcare resource use in adult patients with non-valvular atrial fibrillation?
In a real-world Italian cohort of NVAF patients, NOAC use was associated with fewer bleeding events and lower overall annual healthcare costs compared to VKA use.
Answers are grounded in this paper and cite their sources.
Should not yet change NVAF anticoagulation practice; leaves open residual confounding in this unadjusted Italian cohort.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Esposti et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: